TY - JOUR
T1 - Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood
T2 - An analysis of the JSHCT
AU - Murata, M.
AU - Nishida, T.
AU - Taniguchi, S.
AU - Ohashi, K.
AU - Ogawa, H.
AU - Fukuda, T.
AU - Mori, T.
AU - Kobayashi, H.
AU - Nakaseko, C.
AU - Yamagata, N.
AU - Morishima, Y.
AU - Nagamura-Inoue, T.
AU - Sakamaki, H.
AU - Atsuta, Y.
AU - Suzuki, R.
AU - Naoe, T.
N1 - Funding Information:
We thank all of the physicians at each transplant center and the data managers at the data center of the Japan Society for Hematopoietic Stem Cell Transplantation. This study was supported in part by a Health and Labour Sciences Research Grant (H25-Transplantation-104) from the Ministry of Health, Labour and Welfare, Japan and a Grant-in-Aid for Scientific Research (no. 23591415) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
PY - 2014/3
Y1 - 2014/3
N2 - To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.
AB - To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ≥2 (vs PS 0-1) predicted a lower OS (P=0.044), and RBC transfusion ≥20 times before transplantation (vs transfusion ≤9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.
KW - donor source
KW - engraftment
KW - hematopoietic SCT
KW - idiopathic myelofibrosis
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=84904243249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904243249&partnerID=8YFLogxK
U2 - 10.1038/bmt.2013.180
DO - 10.1038/bmt.2013.180
M3 - Article
C2 - 24270391
AN - SCOPUS:84904243249
SN - 0268-3369
VL - 49
SP - 355
EP - 360
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 3
ER -